Showing results (191-200 of 221) with videos related to
Sort By:
Pageof 23
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2004
A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumorsA Craig Lockhart, Martin Howard, Kenneth R Hande, et al.AJR. American Journal of Roentgenology|May 1, 1986
Thorotrast-induced hepatosplenic neoplasia: CT identificationD W Levy, S Rindsberg, A C Friedman, et al.Cancer Chemotherapy and Pharmacology|May 21, 2005
Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumorsHiroyuki Kobayashi, S Gail Eckhardt, Jennifer A Lockridge, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2007
Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer modelsJeffrey M Albert, Carolyn Cao, Kwang Woon Kim, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumorsAlejandro D Ricart, Jordan D Berlin, Kyriakos P Papadopoulos, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2002
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trialRoy S Herbst, Anne-Marie Maddox, Mace L Rothenberg, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2003
Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectantNeal J Meropol, Robert A Somer, John Gutheil, et al.Oncology (Williston Park, N.Y.)|September 3, 1998
Alternative dosing schedules for irinotecanM L Rothenberg, J G Kuhn, L J Schaaf, et al.European Journal of Clinical Pharmacology|August 31, 2013
Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumorsHuali Wu, Jeffrey R Infante, Vicki L Keedy, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 1998
A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposideL A Hammond, J R Eckardt, R Ganapathi, et al.Pageof 23